Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug243 | Albuterol - Control Wiki | 0.71 |
| drug4669 | prednisolone Wiki | 0.71 |
| drug244 | Albuterol - Experimental Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
We can not predict which wheezing child younger than 3 years of age benefits from systemic glucocorticoid and which one does not. It is not known whether the differences in the efficacy are related to the differences in viral etiology, atopy, immunogical maturity or age of the patient. The study aims to answer the following questions: 1. What is the viral etiology of acute childhood expiratory wheezing? 2. What is the efficacy of prednisolone in relation to age, atopy and viral etiology in acute childhood wheezing? 3. Does prednisolone treatment increase risk for secundary bacterial infection in acute childhood expiratory wheezing? 4. What is the significance of inflammatory markers in predicting the efficacy of systemic steroid or patient outcome in acute childhood expiratory wheezing? Study will follow randomized, double blind, placebo-controlled parallel design. Study will start in Septemper 2000 and will be performed at the Department of Pediatrics, Turku University Hospital, Turku Finland. The study population will be 300 hospitalized wheezing children aged 3 months - 15 years. Investigational drug will be prednisolone, first dose 2 mg/kg, then 2 mg/kg/d/3 (max. 60 mg/vrk) p.o. for 3 d and comparative drug will be placebo tablet similar to investigational drug with the equal dosage. The primary outcome will be the time until ready for discharge. The study will provide new and important information for the diagnostics, treatment, disease outcome and prevention of acute childhood expiratory wheezing.
Metered dose inhalers with spacers are devices capable of providing higher rates of lung deposition of drugs such as beta agonists when compared to conventional nebulizers, but there is no consensus about the optimal dose when this is the device of choice and there is evidence that younger children need proportionally higher doses of albuterol (in μg/kg) when compared to older children. Other factors that may interfere with response to albuterol treatment include the genetics of the beta adrenergic receptor (ADRβ2) and infectious etiology of the wheezing attack. This study will assess the effectiveness of a dose regimen that prioritizes higher doses of albuterol, with doses in μg/kg higher for younger children. Security of this new dosing regimen will be assessed by monitoring clinical side effects and serum levels of albuterol, but the investigators will also examine the presence of 12 different respiratory viruses in these patients and evaluate the influence of ADRβ2 receptor genetics in the response to albuterol. The primary outcome measure will be the need for hospitalization. Secondary outcomes will include a change in clinical score, respiratory rate and forced expiratory volume in the first second, the need for additional treatments and length of stay in the emergency room for those not hospitalized.
Description: Hospital admission was defined as the need to stay in the emergency room for more than 4 hours, due to the failure to meet the discharge criteria (PRAM score ≤ 3 and pulse oximetry, ≥ 92%)
Measure: Hospital Admission Time: Starting at 4 hours post-treatmentDescription: Change in FEV1 one hour post-treatment in comparison with baseline. Spirometry was performed only in subjects older than 6 years and who could perform the maneuver properly.
Measure: Forced Expiratory Volume in the First Second Time: One hour post-treatment in comparison with baselineDescription: Change in the Pediatric Respiratory Assessment Measure (PRAM) score one hour post-treatment in comparison with baseline. The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack. We calculated the difference between the PRAM score measured one hour post treatment and the PRAM score at baseline (PRAM score 1 hour - PRAM score baseline). The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2). minimum value of the difference (Albuterol - Higher Dose, experimental group): -8 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0 minimum value of the difference (Albuterol - Lower Dose, control group): -8 maximum value of the difference (Albuterol - Lower Dose, control group): 0
Measure: Change in PRAM Score After One Hour Time: One hour post-treatmentDescription: Albuterol determination in the plasma was carried out at at discharge or hospital admission (up to 4 hours post treatment), dosage was accomplished by High Performance Liquid Chromatography.
Measure: Albuterol Determination in the Plasma Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: Changes in glucose serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Glucose Serum Levels Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Electrocardiogram performed at baseline
Measure: Electrocardiogram at Baseline Time: at baselineDescription: Change in respiratory rate one hour post-treatment in comparison with baseline.
Measure: Changes in Respiratory Rate After One Hour Time: One hour post-treatment in comparison with baselineDescription: The need for additional therapies such as magnesium sulphate or intravenous albuterol were recorded
Measure: Need for Additional Therapies Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: Change in the Pediatric Respiratory Assessment Measure (PRAM) score at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline. The PRAM score is used to assess the severity of asthma attacks, it ranges from 0 to 15, and the higher the score, the greater the severity of the attack. We calculated the difference between the PRAM score measured at discharge or admission and the PRAM score at baseline (PRAM score discharge or admission - PRAM score baseline). The larger the absolute value of the difference, the better the outcome (e.g., a difference of -4 indicates a better outcome that a difference of -2). minimum value of the difference (Albuterol - Higher Dose, experimental group): -9 maximum value of the difference (Albuterol - Higher Dose, experimental group): 0 minimum value of the difference (Albuterol - Lower Dose, control group): -9 maximum value of the difference (Albuterol - Lower Dose, control group): 1
Measure: Changes in PRAM Score at Discharge or Hospital Admission Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Changes in potassium serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Potassium Serum Levels Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Changes in bicarbonate serum levels at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Bicarbonate Serum Levels Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Changes in respiratory rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Respiratory Rate at at Discharge or Hospital Admission. Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Change in pulse oximetry one hour post-treatment in comparison with baseline
Measure: Change in Pulse Oximetry One Hour Post-treatment Time: One hour post-treatment in comparison with baselineDescription: Changes in pulse oximetry at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Pulse Oximetry at Discharge or Hospital Admission. Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment) in comparison with baseline.Description: Change in heart rate one hour post-treatment in comparison with baseline.
Measure: Changes in Heart Rate After One Hour Time: One hour post-treatment in comparison with baselineDescription: Changes in heart rate at discharge or hospital admission (up to 4 hours post treatment) in comparison with baseline.
Measure: Changes in Heart Rate at Discharge or Hospital Admission Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: Electrocardiogram one hour post-treatment to identify possible rhythm disturbances.
Measure: Electrocardiogram One Hour Post-treatment. Time: One hour post-treatmentDescription: Electrocardiogram at discharge or hospital admission to identify possible rhythm disturbances.
Measure: Electrocardiogram at Discharge or Hospital Admission Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: lengths of stay in the emergency room for discharged patients
Measure: Lengths of Stay in the Emergency Room Time: one to four hoursDescription: Admission rates in patients with and without any of the following viruses detected by PCR in nasal lavage samples: Adenovirus; Bocavirus; Coronavirus; Enterovirus (Echovirus); Influenza (A H3N2, A H1N1/2009, B and C); Metapneumovirus (subtypes A and B); Parainfluenza 1, 2, 3 and 4 (subtypes A and B); Rhinovirus; Respiratory Syncytial Virus type A and Respiratory Syncytial Virus type B.
Measure: Admission Rates in Patients With and Without Any Virus Detected Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: Admission rates in patients with and without rhinovirus detected by PCR in nasal lavage samples.
Measure: Admission Rates in Patients With and Without Rhinovirus Detect Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Description: Admission rates in patients with the Arg16Gly polymorphisms of the beta-2 adrenergic receptor (Arg16Gly, Arg16Arg and Gly16Gly genotypes).
Measure: Admission Rates in Patients With the Arg16Gly Polymorphisms Time: at discharge or admission (up to 4 hours post treatment, minimum 1 hour, maximum 4 hours post treatment)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports